Clinical Trial Update: Phase I/IIa Dose-escalation Clinical Study of VAC-3S [Phase 1, Phase 2]

View source ↗

Summary

The Phase I/IIa dose-escalation study of VAC-3S in HIV-1 infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• VAC-3S

Snippet

Sponsor: InnaVirVax | Conditions: HIV-1 Infection | Phase 1, Phase 2 | Status: COMPLETED